Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.13 Average Target Price from Brokerages

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) have earned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $11.1250.

Several equities research analysts have recently issued reports on CRDF shares. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Cardiff Oncology in a report on Wednesday, January 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Wednesday, January 21st. Finally, Noble Financial started coverage on Cardiff Oncology in a report on Monday, January 5th. They issued an “outperform” rating and a $12.00 price target on the stock.

Cardiff Oncology Trading Up 8.1%

CRDF stock opened at $1.60 on Thursday. The stock has a market capitalization of $107.78 million, a PE ratio of -2.03 and a beta of 1.33. Cardiff Oncology has a 12-month low of $1.48 and a 12-month high of $4.99. The stock’s 50 day simple moving average is $2.52 and its 200 day simple moving average is $2.38.

Cardiff Oncology (NASDAQ:CRDF) last announced its earnings results on Thursday, November 6th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.03. Cardiff Oncology had a negative return on equity of 77.21% and a negative net margin of 10,064.27%.The firm had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.12 million. On average, research analysts predict that Cardiff Oncology will post -0.99 earnings per share for the current year.

Institutional Trading of Cardiff Oncology

Several institutional investors and hedge funds have recently made changes to their positions in the business. Blair William & Co. IL grew its holdings in shares of Cardiff Oncology by 44.1% in the second quarter. Blair William & Co. IL now owns 2,524,118 shares of the company’s stock worth $7,951,000 after purchasing an additional 772,844 shares during the last quarter. Laurion Capital Management LP boosted its position in Cardiff Oncology by 37.2% in the 3rd quarter. Laurion Capital Management LP now owns 2,465,872 shares of the company’s stock valued at $5,080,000 after buying an additional 668,590 shares during the period. Acorn Capital Advisors LLC grew its stake in Cardiff Oncology by 39.3% in the 3rd quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock worth $4,042,000 after acquiring an additional 553,317 shares in the last quarter. Flputnam Investment Management Co. increased its position in shares of Cardiff Oncology by 1,008.8% during the third quarter. Flputnam Investment Management Co. now owns 597,233 shares of the company’s stock worth $1,230,000 after acquiring an additional 543,370 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of Cardiff Oncology during the second quarter worth approximately $411,000. 16.29% of the stock is currently owned by institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.